Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia 2014-03, Vol.20 (2), p.294-300
• Main Authors: Sommer, J. M., Moore, N., McGuffie-Valentine, B., Bardan, S., Buyue, Y., Kamphaus, G. D., Konkle, B. A., Pierce, G. F.
• Format: Article
• Language: English
• Subjects: B-domain deleted; Blood Coagulation Tests - methods; Blood Coagulation Tests - standards; chromogenic substrate assay; factor VIII; Factor VIII - metabolism; Factor VIII - therapeutic use; field study; Hemophilia A - blood; Hemophilia A - drug therapy; Humans; one-stage clotting assay; Original; Reagent Kits, Diagnostic; Recombinant Proteins - blood; Recombinant Proteins - therapeutic use; Reproducibility of Results; Sensitivity and Specificity
• ISSN: 1351-8216; 1365-2516
• DOI: 10.1111/hae.12296

Summary Discrepancies exist for some of the modified coagulation factors when assayed with different one‐stage clotting and chromogenic substrate assay reagents. The aim of this study was to evaluate the performance of a recombinant factor VIII Fc fusion protein (rFVIIIFc), currently in clinical development for the treatment of severe haemophilia A, in a variety of one‐stage clotting and chromogenic substrate assays in clinical haemostasis laboratories. Haemophilic plasma samples spiked with rFVIIIFc or Advate® at 0.05, 0.20 or 0.80 IU mL−1 were tested by 30 laboratories using their routine procedures and plasma standards. Data were evaluated for intra‐ and inter‐laboratory variation, accuracy and possible rFVIIIFc‐specific assay discrepancies. For the one‐stage assay, mean recovery was 95% to 100% of expected for both Advate® and rFVIIIFc at 0.8 IU mL−1. Intra‐laboratory percent coefficient of variance (CV) ranged from 6.3% to 7.8% for Advate®, and 6.0% to 10.3% for rFVIIIFc. Inter‐laboratory CV ranged from 10% for Advate® and 16% for rFVIIIFc at 0.8 IU mL−1, to over 30% at 0.05 IU mL−1 for both products. For the chromogenic substrate assay, the average FVIII recovery was 107% ± 5% and 124% ± 8% of label potency across the three concentrations of Advate® and rFVIIIFc, respectively. Plasma rFVIIIFc levels can be monitored by either the one‐stage or the chromogenic substrate assay routinely performed in clinical laboratories without the need for a product‐specific rFVIIIFc laboratory standard. Accuracy by the one‐stage assay was comparable to that of Advate®, while marginally higher results may be observed for rFVIIIFc when using the chromogenic assay.